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Large chromosomal regions can be suppressed in cancer cells as denoted by hypermethylation of neighbouring CpG islands and
downregulation of most genes within the region. We have analysed the extent and prevalence of long-range epigenetic silencing at
2q14.2 (the first and best characterised example of coordinated epigenetic remodelling) and investigated its possible applicability
as a non-invasive diagnostic marker of human colorectal cancer using different approaches and biological samples. Hypermethylation
of at least one of the CpG islands analysed (EN1, SCTR, INHBB) occurred in most carcinomas (90%), with EN1 methylated in 73 and
40% of carcinomas and adenomas, respectively. Gene suppression was a common phenomenon in all the tumours analysed and
affected both methylated and unmethylated genes. Detection of methylated EN1 using bisulfite treatment and melting curve (MC)
analysis from stool DNA in patients and controls resulted in a predictive capacity of, 44% sensitivity in positive patients (27% of overall
sensitivity) and 97% specificity. We conclude that epigenetic suppression along 2q14.2 is common to most colorectal cancers and the
presence of a methylated EN1 CpG island in stool DNA might be used as biomarker of neoplastic disease.
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In mammals, DNA methylation is an epigenetic modification that
mainly occurs in the cytosine residue within the CpG dinucleotide,
which is underrepresented along the genome. We also find short
stretches of CpG-dense DNA, called CpG island, normally free of
methylation and frequently associated with the 50 promoter of
many housekeeping or tissue-specific genes (Feinberg and Tycko,
2004; Baylin, 2005; Esteller, 2007a). Promoter CpG islands can
become de novo methylated in a cancer cell leading to silencing of
the associated gene (Baylin, 2005; Esteller, 2007a). Epigenetic
inactivation of tumour suppressor genes is a well-characterised
mechanism that is found in virtually all types of neoplasms. Many
genes that are silenced by promoter hypermethylation in tumours
play important roles in carcinogenesis; these include genome
stability, cell-cycle entrance, proliferation, apoptosis, etc. (Baylin,
2005; Esteller, 2007a). The analysis of these epigenetic alterations
has multiple applications including their use as prognostic factors,
early disease markers, and predictors of response to therapy
(Laird, 2003; Baylin, 2005; Esteller, 2007a).
Studies to date, using either candidate gene approaches or global
surveys have shown that multiple, but discrete CpG islands can be
methylated concurrently in any one cancer (Laird, 2003). In a
recent study, a genome-wide DNA methylation screening approach
showed coordinated hypermethylation of multiple CpG islands
spanning a 1Mb region in colorectal cancer (Frigola et al, 2006). It
is interesting that, hypermethylation of these CpG islands was
accompanied by long-range epigenetic silencing (LRES) of a 4-Mb
chromosomal region mapping at 2q14.2 affecting all the genes
regardless of whether their promoters were associated with CpG
islands and if these were methylated or not (Frigola et al, 2006).
Beyond this first evidence supporting, the existence of a new
mechanism of gene inactivation in cancer, later studies indicate
that LRES may also occur in other chromosomal regions and
cancers (Stransky et al, 2006; Hesson et al, 2007; Hitchins et al,
2007; Rodriguez et al, 2008). This region encompasses the
Engrailed-1 (EN1) gene encoding a homeobox transcription factor.
EN1 plays a major role in development and upon deregulation in
neoplasia (Bachar-Dahan et al, 2006; Rauch et al, 2007).
This work aims to determine the extent and prevalence of gene
silencing in the chromosomal region 2q14.2 in human colorectal
cancer and its possible association with the clinicopathological
features of the tumours. We have also investigated the utility of
one of the hypermethylated genes (EN1) as a diagnostic marker in
stool and serum DNA samples of colorectal cancer patients.
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sMATERIALS AND METHODS
Samples
A series of 108 patients pre-operatively diagnosed as having
colorectal cancer and operated upon with curative or palliative
intention between 1996 and 1998 at the Ciutat Sanita `ria i
Universita `ria de Bellvitge was used. This series was part of a larger
collection of patients prospectively included in a study designed to
evaluate the prognostic value of genetic and epigenetic alterations
(Gonzalez-Garcia et al, 2000; Vendrell et al,2 0 0 5 ) .D N Am e t h y l a t i o n
profiles were analysed in all 108 tumours and their normal tissue
counterpart. A subgroup of 17 carcinomas were microdissected and
the tumour infiltration front with 475% tumour cell content, as
assessed by visual examination of hematoxylin–eosin stained
preparations, was selected for gene expression analysis. Special care
was taken to discard areas with necrotic tissue or harbouring a high-
inflammatory component. Clinicopathological information was
available for 91 cases (see Supplementary Table 1). Mean follow-
up was 79.9±20.3 months. Additionally, 10 colorectal adenomas
were obtained from the Hospital de la Santa Creu i Sant Pau
(Barcelona, Spain). In all cases, surgical specimens were collected in
the operating room and immediately taken to the Pathology
Department in ice. Carcinomas and paired normal samples were
snap frozen within 2h after removal and then stored at  801C.
To study EN1 methylation as a diagnostic marker in colorectal
cancer a different series of 30 patients with available DNA from
normal and tumour tissues, stool and serum was used. Additionally,
stool and serum DNA was available from 30 healthy donors
matched by age and sex with the patient group. Stool DNA was
extracted from cellular material obtained after centrifugation of
bowel lavage or solid stools as described earlier (Puig et al, 1999).
Serum DNA was obtained as described earlier (Castells et al, 1999).
The study protocol was approved by the Ethics Committee.
No chemo- or radiotherapy was given prior to surgery. DNA and
RNA amenable for genetic analyses were obtained using standard
procedures.
DNA methylation analysis
Bisulfite sequencing Bisulfite conversion was carried out using
2mgo fD N Af o r1 6 ha t5 5 1C under conditions described earlier
(Stirzaker et al, 2004). A nested PCR was carried out in all cases to
obtain a fragment of each one of the CpG islands to be analysed (see
primer sequences in Supplementary Table 2). Bisulfite sequencing
was carried out using the BigDye Terminator cycle sequencing kit
(Applied Biosystems, Carlsbad, CA, USA). The degree of methylation
was calculated by comparing the peak height of the cytosine signal
with the peak height of the cytosine plus thymine signal as described
(Melki et al, 1999).
Real-time PCR temperature dissociation (melting curve (MC))
Bisulfite conversion and PCRs were carried out as for bisulfite
sequencing, except for the nested PCR, that was carried out using a
Light Cycler 2.0 (Roche, Mannheim, Germany) and the Fast Start
DNA Master Sybr Green I mix (Roche) with real-time detection
as described (Frigola et al, 2006). Melting curves (MC) from fully
unmethylated samples (as determined by bisulfite sequencing)
were used as controls.
Methylation specific PCR (MSP) Bisulfite conversion and PCRs
were carried out as for bisulfite sequencing, except for the nested
PCR, which was carried out using specific primers for methylated
and unmethylated DNA (Supplementary Table 2).
Gene expression analysis
cDNA was obtained by retrotranscription of 500ng of RNA
with M-MLV retrotranscriptase (Invitrogen, Carlsbad, CA, USA)
using random hexamers (Amersham Biosciences, Chalfont
St Giles, UK) at 371C for 1h. cDNA levels were quantified using
the Light Cycler 2.0 real-time PCR system with Fast Start Master
SYBR Green I kit (Roche). For a 10ml PCR reaction volume, 1mlo f
cDNA and 9ml of mastermix were added to each capillary.
Mastermix was prepared to a final concentration of 3.5mM MgCl2
and 0.5mM of each primer. Primers used for expression analysis are
listed in Supplementary Table 3.
Statistical analysis
All results are expressed as a mean±s.d. Statistical differences
between variables were analysed with unpaired/paired t-tests or
analysis of variance (ANOVA), as appropriate. Contingency tables
were analysed by the w
2 or Fisher’s-exact test. Survival curves were
traced according to the Kaplan–Meier method. The statistical
significance between survival curves was tested using the log-rank
test. All P-values are calculated from two-sided statistical tests.
RESULTS
Frequency and extent of 2q14.2 CpG island methylation
in human colorectal carcinomas and adenomas
The three CpG islands associated with the promoter region of the
genes EN1, SCTR and INHBB mapping to 2q14.2 have been
identified earlier to be hypermethylated in colorectal cancer
(Frigola et al, 2006). These islands have been characterised by
direct bisulfite sequencing and MC analysis in an extended series
of 108 colorectal carcinomas with their paired normal tissue and in
10 adenomas. Two more CpG islands corresponding to genes
PTPN4 and RALB were also analysed but remained unmethylated
in all the normal and tumour samples (data not shown). An
excellent agreement between results obtained by bisulfite sequen-
cing and MC analysis was observed. Illustrative examples of non-
methylation, and partial and full methylation are shown in
Supplementary Figures 1 and 2. Methylation of any of the CpG
islands analysed was very rare in normal colon mucosa (only three
cases; Supplementary Table 4) and always appeared as a low
percentage of methylated molecules. Clonal analysis of normal and
tumour samples with partial methylation showed the coexistence
of densely methylated with poorly methylated molecules in all
cases, confirming the presence of cell populations with hetero-
geneous DNA methylation profiles (data not shown). On the other
hand, most carcinomas (82 out of 91, 90%) exhibited methylation
of at least one gene (Supplementary Figure 3A), with EN1 as the
most frequently methylated gene in both carcinomas (66 out of 90,
73%) and adenomas (4 out of 10, 40%); SCTR also presented a high
level of methylation in carcinomas (48 out of 90, 53%) and
adenomas (3 out of 10, 33%); whereas INHBB showed the lowest
rate of methylation (23 out of 91 carcinomas, 25%, and none of the
10 adenomas) (Figure 1 and Supplementary Table 4).
The methylation status of three additional CpG islands (CpG104,
CpG 41 and CpG 173) flanking the EN1 CpG island (CpG128)
(see Supplementary Figure 3B) was determined in a subset of
23 colon carcinomas and their matched normal mucosa from the
series of 108 cases by PCR MC analysis. For each gene, a subset
of 50% of the samples were re-analysed by bisulfite sequencing
and all results were confirmed. As expected, none of the normal
mucosa samples exhibited methylation in any of the six CpG
islands analysed. In this subgroup, SCTR CpG island (CpG67) was
the most frequently methylated (21 out of 23, 91%), followed
by CpG173 (20 out of 23, 87%) and EN1 (17 out of 23, 74%)
(Supplementary Figure 3C). The methylation status was indepen-
dent for all the CpG islands analysed (data not shown) and no
correlation between the methylation frequency and CpG island
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was observed.
Genes at 2q14.2 are down-regulated in most
colorectal tumours
To get insights into the extent of the gene suppression and its
association with promoter hypermethylation, we analysed by
real-time PCR the expression of eight genes mapping to 2q14.2
region in an independent series of 17 colorectal tumour samples
and their matched normal pairs. Tumour tissues were micro-
dissected to minimise the presence of non-tumour cells in the
sample. The methylation state of five of the eight genes was
determined using the MC analysis. EN1 expression was undetect-
able in all the samples. In agreement with earlier observations in
pooled samples (Frigola et al, 2006), most of the genes were down-
regulated in all the tumours as compared with their paired normal
mucosa (Figure 2). Interestingly, suppression affected the genes
with methylatable CpG island (SCTR and INHBB) irrespective of
its methylated state, genes with unmethylated CpG island (PTPN4,
RALBB, TSN), and genes without CpG island (GLI2, MARCO).
These results indicate that epigenetic suppression of the region is
a very frequent event in colorectal cancer and suggest that DNA
hypermethylation of some of the CpG islands is a secondary
manifestation of the silencing.
Genetic and clinicopathological features of the colorectal
tumours with and without methylation in EN1, SCTR
and INHBB
Next, we wondered whether the methylation status of each one of
the CpG islands analysed might be associated with genetic and
clinicopathological characteristics of colorectal cancer patients.
Sex, Dukes’ stage, age, tumour localisation, the presence of muta-
tions in the p53 and K-ras genes and microsatellite instability
(MSI), and follow-up parameters were considered together with
the methylation status of the EN1, SCTR and INHBB CpG islands
in the series of 91 patients. Early stage tumours showed a higher
proportion of methylated genes (P¼0.020) (Figure 1B and Supple-
mentary Table 1) and SCTR was the gene exhibiting the higher
differences (P¼0.015). In a subset of 50 of the 91 cases, chromo-
some profiles determined by comparative genomic hybridisation
were available (Vendrell et al, 2007). No associations with specific
chromosomal aberrations or with global indicators of chromo-
somal instability were observed. Regarding disease outcome, the
number of methylated genes did not seem to modify the survival
rate (data not shown). At the single gene level, patients with
methylation at INHBB or EN1 showed a worse overall survival,
although the differences were only statistically significant for
INHBB and when the methylation status of both promoters was
combined, in which case differences were more prominent
(Figure 3).
Detection of EN1 methylation as a diagnostic tool in
colorectal cancer
The elevated methylation frequencies of EN1 in colorectal adeno-
mas and carcinomas lead us to evaluate its possible application as
a diagnostic marker of colorectal cancer. We determined the
methylation status of EN1 CpG island in the DNA obtained from
stools, serum and the corresponding tumour samples in an inde-
pendent series of 30 colorectal cancer patients. Stools and serum
DNA obtained from 30 healthy individuals paired by age and sex
were used as control group. We applied different techniques to
determine the methylation status, namely direct bisulfite sequenc-
ing (BS), analysis of MCs and methylation-specific PCR (MSP)
(Supplementary Figure 4). To determine the true positive and false
positive obtained with each technique, the result obtained from the
stool or serum DNA was compared with that from the respective
tumour using the same technique. Full data set is provided in
Supplementary Figures 5–9 and Supplementary Tables 5 and 6.
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Figure 2 Relative expression levels of the eight genes analysed across
the 2q14.2 chromosome region in 17 colorectal tumour tissues and their
paired normal mucosa. The log2 of the tumour/normal ratio is represented.
Negative values indicate downregulation in the tumour as compared with
the respective normal tissue. Expression levels were normalised using the
18S rRNA expression as control. Methylation status was determined using
melting curve (MC) analysis and is depicted in column filling as indicated.
Grey column indicates genes without promoter CpG island (MARCO,
GLI2) or not analysed (TSN).
80 20
15
10
5
0
60
40
20
0
Normal
Adenoma
Dukes B
Dukes C
Dukes D
Carcinoma
P
e
r
c
e
n
t
a
g
e
N
o
 
o
f
 
t
u
m
o
u
r
s
EN1
SCTR
INHBB
0123
Figure 1 DNA methylation across 2q14.2 in colorectal cancer.
(A) Frequencies of the methylation in EN1, SCTR and INHBB CpG
islands in normal colonic mucosa, and colorectal adenomas and carcinomas.
Y-axis indicates the percentage of samples with methylation for each gene.
(B) Incidence of methylation in colorectal carcinomas according Dukes’
stage. Y-axis indicates the number of tumours exhibiting methylation in 0, 1,
2 or 3 of the CpG islands analysed (EN1, SCTR and INHBB).
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sSamples exhibiting X25% methylation (depicted as light grey
in figures) in at least half of the analysed CpG sites or X50%
methylation (depicted as dark grey dots in figures) in at least 1/4 of
the analysed CpG sites were considered as methylated. MC analysis
appeared as the most efficient method to detect EN1 methylation
in stool DNA with a sensitivity of 44% (8 out of 18) and 27% (8 out
of 30) considering patients with methylated tumours or all
patients, respectively (Figure 4 and Supplementary Table 5). In
patients with methylation in the tumours, 17% (3 out of 17) were
detected by bisulfite sequencing and 14% (4 out of 27) by MSP. In
serum, the sensitivity of MC analysis was lower (2 out of 18, 11%).
All samples from healthy donors were unmethylated as deter-
mined by MC analysis but with a single exception in one stool
DNA. Bisulfite sequencing of this sample showed full methylation
in three CpGs and full unmethylation in the rest of CpG sites. As
two of these methylated CpG sites were located in the priming
region used for MSP analysis, neither methylated nor unmethyl-
ated product was obtained using this technique (Figure 4 and
Supplementary Table 6). Altogether, MC analysis appears to be
the most accurate method to detect the presence of EN1
methylation in stool DNA.
DISCUSSION
Here we report the high prevalence of coordinated epigenetic
silencing at 2q14.2 in most if not all colorectal carcinomas. We also
show that hypermethylation is an early event that can be selected
for during tumourigenesis. This is in concordance with studies at
genomic level showing the accumulation of hypermethylation
during tumour progression (Toyota et al, 1999; Frigola et al, 2005).
The commonness of LRES in colorectal cancer has been confirmed
in independent studies, that have also noted the association
between hypermethylation of the genes in the 2q14.2 region and
other CpG islands (Karpinski et al, 2008).
The gene expression down-regulation in tumour affected all
genes, irrespectively of the presence of CpG island or the methyl-
ation status, confirming the earlier results obtained in cell lines
and pooled normal and tumour DNAs (Frigola et al, 2006). The
suppression of 2q14.2 in all the tumours analysed stresses its high
prevalence in colorectal cancer. Moreover, the lack of association
with DNA methylation suggests that the latter is a secondary
phenomenon (Mutskov and Felsenfeld, 2004; Stirzaker et al, 2004;
Strunnikova et al, 2005). The arbitrary distribution of DNA
methylation along the methylatable CpG islands (Supplementary
Figure 3) is also consistent with a model in which regional
suppression is followed by spurious DNA methylation of silenced
CpG islands showing appropriate epigenetic signatures (Stirzaker
et al, 2004). It is of note that some of the genes exhibited wide
variations in their expression levels in normal colonic mucosa.
This implies that contaminating non-tumour cells may mask
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Figure 3 Overall survival in colorectal cancer patients according to the
methylation status of INHBB and EN1. Tumours with methylated INHBB
or EN1 showed a reduced survival rate, but differences reached only
statistical significance for INHBB or the combination of both, INHBB
and EN1.
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Figure 4 Detection of EN1 methylation in stool and serum DNA as
a diagnostic marker of colorectal cancer. ‘True positive’ indicates the
percentage of all colorectal cancer patients with a methylated marker
in both the tumour and the test sample (stool or serum DNA). ‘False
positive’ corresponds to the percentage of healthy individuals with a
methylated result in the test sample. The best score was obtained when
melting curve (MC) analysis was applied to detect EN1 methylation in stool
DNA (27% of overall sensitivity, 44% sensitivity in positive tumours, and
97% specificity).
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sthe downregulation in tumour samples and, hence, microdis-
section is critical to obtain a precise assessment of differential
expression.
The methylation state of the gene promoters did not seem to be
associated with clinicopathological or genetic features of the
tumours. Some trends were observed, but of little significance and
might result from the performance of multiple statistical tests. The
large prevalence of gene suppression across 2q14.2 and the limited
accuracy of CpG island hypermethylation as a surrogate marker of
gene silencing seem to hinder this study. Therefore, the implica-
tions of this alteration in colorectal cancer remain unknown and
future studies at cellular level are required to determine its causes
and consequences. On the other hand, the possible association of
EN1 and INHBB methylation with worse outcome in early stages
of the disease deserves further investigation, as it might have a
prognostic value in a subgroup of patients that may benefit from
more aggressive therapies.
DNA testing in non-invasive samples seems to be a feasible
approach that can complement and probably outperform other
screening tests for colorectal cancer (Dong et al, 2001; Ahlquist,
2002; Traverso et al, 2002), although its routine clinical application
is still under debate (Brenner and Rennert, 2005; Capella, 2005).
De novo DNA methylation in multiple CpG islands is a common
event in cancer and a large number of new tumour biomarkers
have appeared as promising candidates (Esteller, 2007b). Detection
of CpG island methylation in human DNA isolated from stool
(Belshaw et al, 2004; Leung et al, 2004; Chen et al, 2005; Zitt et al,
2007) or serum (Zou et al, 2002; Leung et al, 2005; Nakayama et al,
2007; Lofton-Day et al, 2008) has been proposed as a new strategy
for the early diagnosis of colorectal neoplasia. Other studies with
comparable series have reported high sensitivities for different
methylation markers used alone (Chen et al, 2005; Lenhard et al,
2005; Huang et al, 2007a; Wang and Tang, 2008) or in combina-
tion (Leung et al, 2004; Petko et al, 2005; Huang et al, 2007b;
Lofton-Day et al, 2008), although a wider application is usually
hinder by a limited specificity.
The high prevalence of methylation in EN1 CpG island (three
out of every four carcinomas show hypermethylation of this gene)
together with its possible functional role in cancer (Bachar-Dahan
et al, 2006; Rauch et al, 2007) lead us to evaluate its putative
clinical usefulness as a diagnostic marker of disease. Of the three
techniques used, MSP seems to be extremely sensitive but results
in a high rate of positive results in healthy subjects. MC analysis
appeared as the best alternative based on its simplicity and per-
formance: 97% specificity and 44% sensitivity in patients with a
methylated EN1 in the tumour. This corresponds to a 27% overall
sensitivity when non-informative patients (showing unmethylated
EN1 in the tumour) are considered. As shown in dilution experi-
ments (Supplementary Figure 2), dissociation temperatures for
partially methylated DNA can be distinguished from unmethylated
DNA even when just a fraction (10%) of the cells show methyl-
ation. Although the short number of cases analysed precludes a
definitive conclusion, the diagnostic utility of EN1 methylation by
itself or as part of a panel of biomarkers deserves further consid-
eration and evaluation in large series of cases.
In summary, our study shows the high prevalence of epigenetic
suppression along 2q14.2 in colorectal cancer. This suppression is
manifested in biopsied tumour samples as global downregulation
of all the genes mapping to this region and DNA methylation of
several CpG islands as a likely secondary event. These observations
confirm that long-range epigenetic silencing across 2q14.2 is a
feature of most colon cancers. Finally, the high prevalence of EN1
CpG island methylation makes this alteration a good candidate as
a non-invasive early diagnostic target. Our preliminary analysis
indicates the feasibility of the detection of methylated EN1
promoter in stool DNA as a marker of disease.
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